Viral INfections in the Young Lung- The VINYL Clinical Consortium- Data Analytics and Coordinating Center (DACC)(U24 Clinical Trial Optional)
ID: 359952Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359952

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-008.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for a cooperative agreement to establish a Data Analytics and Coordinating Center (DACC) as part of the Viral Infections in the Young Lung (VINYL) Clinical Consortium. The primary objective of this initiative is to conduct deep phenotyping and longitudinal follow-up of 1,500 infants and toddlers (ages 0-2) hospitalized with viral lower respiratory tract infections (LRTI), specifically focusing on conditions such as acute bronchiolitis and pneumonia, to better understand their impact on lung health. This project is critical for addressing significant knowledge gaps in the management and outcomes of viral infections in young children, with an anticipated funding amount of $800,000 for fiscal year 2026. Applications are due by November 10, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HL-26-008-Full-Announcement.html
    RFA-HL-26-008.html
    The Department of Health and Human Services is seeking applications for a Data and Analytics Coordinating Center (DACC) to support the Viral Infections in the Young Lung (VINYL) Clinical Consortium. This U24 cooperative agreement aims to establish a DACC that will facilitate clinical activities, data harmonization, and the creation of a public data platform for a multi-site study on viral lower respiratory tract infections (LRTI) in hospitalized children aged 0-2 years. The VINYL Consortium will enroll 1500 participants for deep phenotyping and longitudinal follow-up until ages 4-5. The DACC will manage data, including imaging and biospecimens, and ensure rapid sharing with the broader research community. Key responsibilities include protocol development, data management, statistical analysis, website maintenance, and fostering skill development for future researchers. The project period is up to seven years, with an anticipated funding of $800,000 in FY26 for one award. Applications are due by November 10, 2025.
    Similar Opportunities
    Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming opportunity for a cooperative agreement titled "Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)." This initiative aims to support a consortium focused on phenotyping children aged 0-2 years who experience severe viral lower respiratory tract infections (LRTI), with follow-up assessments until preschool age to evaluate pulmonary sequelae. The program is significant for advancing research in pediatric respiratory health and will utilize the UG3/UH3 activity code for funding, with applications not currently being solicited to allow potential applicants time to prepare. Interested parties can reach out to the Division of Lung Diseases at NHLBI via email at nhlbidldgrants@nhlbi.nih.gov for further information, with an estimated synopsis posting date of August 22, 2025, and a projected award date of May 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Viral INfections in the Young Lung (VINYL) Clinical Consortium, aimed at supporting research on severe viral lower respiratory tract infections (LRTI) in children aged 0-2 years. This initiative will involve the establishment of a consortium to phenotype affected children and follow them until preschool age to assess pulmonary sequelae, utilizing a phased award structure to fund various centers, including a Data and Analytics Coordinating Center and multiple Clinical Centers. The total funding available is projected to be up to $31.6 million, with the NOFO expected to be published in February 2025 and applications due by June 2025, leading to funding decisions anticipated in February 2026. Interested applicants should prepare their proposals in advance of these deadlines.
    IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) through a cooperative agreement. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive data portal and cataloging variant impacts, while also facilitating consortium activities and collaborations within the broader research community. This initiative is crucial for enhancing the understanding of genomic variation and its implications in health. The estimated total program funding is $1,200,000, with one award anticipated, and the application process is expected to open in 2025, with a due date later that year. For further inquiries, interested applicants can contact Dr. Stephanie A. Morris at morriss2@mail.nih.gov or by phone at 301-435-5738.
    Impact of Initial Influenza Exposure on Immunity in Infants
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants," aimed at advancing research on how influenza infections and vaccinations affect infant and childhood immunity. The initiative seeks to establish and characterize longitudinal cohorts of infants and mother-infant dyads to investigate the influence of initial exposure to influenza antigens on immune responses to subsequent infections and vaccinations. This research is critical for developing durable and broadly protective influenza vaccines. The estimated total program funding is $10 million, with three awards expected, and interested applicants can reach out to Dr. Michelle M. Arnold at michelle.arnold@nih.gov or by phone at 301-761-7324. Key deadlines include an estimated synopsis close date of February 11, 2026, and an estimated award date of December 1, 2026.
    Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center through a Cooperative Agreement. This initiative aims to enhance the Pediatric Data Resource, focusing on expanding data sharing, providing training in cloud-based computational analysis, and facilitating data use for researchers with limited bioinformatics training, ultimately contributing to advancements in understanding childhood cancer and congenital anomalies. The estimated total program funding is $5,200,000, with applications not currently being solicited; however, potential applicants are encouraged to prepare collaborative projects in anticipation of the upcoming Notice of Funding Opportunity (NOFO), which is expected to be published by July 30, 2025, with a closing date for synopsis on October 30, 2025. For further inquiries, interested parties may contact Dr. Concepcion R. Nierras at 301-435-5840 or via email at concepcion.nierras@nih.gov.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    Infectious Diseases Clinical Trials Network (IDCTN)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Data Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity for the establishment of the Data Coordinating Center (DCC) for the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC). The DCC will play a crucial role in coordinating collaborations among genetic research centers, managing participant enrollment, biospecimen collections, and overseeing data submission to central databases, all aimed at advancing research in inflammatory bowel disease (IBD). This initiative is vital for improving medical management and precision medicine for IBD patients, as it seeks to develop new predictors of disease outcomes through the integration of genetic, clinical, and environmental data. The estimated total funding for this program is $1,600,000, with one award expected to be made. Interested applicants can reach out to Dr. Ludmila Pawlikowska at Ludmila.pawlikowska@nih.gov or by phone at 301-480-9372 for further information. The application period is open until November 1, 2026, with an anticipated award date of July 1, 2027.
    Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the Genome Sequencing Center as part of the Gabriella Miller Kids First Pediatric Research Program, aimed at advancing research into childhood cancer and congenital anomalies. This initiative will support the addition of data to existing resources, enhance data types as technologies evolve, and incorporate clinic-based data sources to better understand the genetic pathways of these disorders. With an estimated total program funding of $6.6 million, this cooperative agreement does not require cost sharing and is open to small businesses. Interested applicants are encouraged to prepare for the upcoming Notice of Funding Opportunity (NOFO), with an estimated synopsis posting date of July 30, 2025, and a closing date of October 30, 2025. For further inquiries, potential applicants can contact Dr. Concepcion R. Nierras at 301-435-5840 or via email at concepcion.nierras@nih.gov.